Bladder paraganglioma (pheochromocytoma) is a rare neuroendocrine tumor arising from chromaffin cells of the sympathetic nerve ganglia innervating the detrusor muscle of the bladder wall. It accounts for 0.05-0.1% of all bladder tumors and 1% of all pheochromocytomas. Most commonly seen in women aged 20-40 years. The tumor can secrete catecholamines (adrenaline, noradrenaline) and paroxysmal hypertension, palpitations, headache, and sweating attacks during micturition are pathognomonic — these symptoms result from mechanical stimulation of the tumor during bladder distension and voiding. Functional catecholamine secretion is present in 50-80% of patients. The tumor is hypervascular and shows prominent enhancement on CT/MRI. Very high signal intensity on T2 MRI ('light bulb sign') is characteristic. 10-15% of cases show malignant behavior (metastasis). MIBG scintigraphy is valuable for diagnosis and follow-up. Biopsy is contraindicated — risk of catecholamine crisis.
Age Range
20-60
Peak Age
40
Gender
Female predominant
Prevalence
Bladder paraganglioma develops from chromaffin cells originating from the neural crest during embryological development. These cells normally concentrate in the adrenal medulla but can settle along the sympathetic chain — sympathetic ganglia in the bladder wall can also harbor chromaffin cells. Tumor cells contain catecholamine synthesis enzymes (tyrosine hydroxylase, dopamine beta-hydroxylase, PNMT) and can produce functional catecholamines (noradrenaline > adrenaline). The tumor's hypervascularity results from a rich capillary network — the dense sinusoidal vascularity characteristic of neuroendocrine tumors is seen as prominent arterial enhancement on CT/MRI. The very high signal on T2 MRI ('light bulb sign') results from the tumor's high vascularity, interstitial edema, and loose stromal structure — free water content is very high. Catecholamine release during micturition is triggered by mechanical pressure on the tumor during bladder contraction — this stimulates exocytosis of catecholamine granules. Malignant paraganglioma (10-15%) shows local invasion and/or lymphatic/hematogenous metastasis — histological benign-malignant distinction is difficult; presence of metastasis is the malignancy criterion.
Very high signal intensity of the bladder intramural mass approaching simple fluid on T2W MRI — like a bright light bulb. This finding results from paraganglioma's rich vascularity, loose stromal structure, and high free water content. Reliably distinguishes from other bladder tumors and plays a critical role in pre-biopsy diagnosis — non-invasive diagnosis is important due to biopsy contraindication (catecholamine crisis risk).
Very high signal intensity well-defined intramural mass on the bladder wall on T2W MRI — 'light bulb sign'. Signal intensity is comparably high to simple fluid. Homogeneous high T2 signal reflects the tumor's vascular structure and loose stromal content. This finding is pathognomonic for paraganglioma and reliably distinguishes from other bladder tumors.
Report Sentence
A very high signal intensity well-defined intramural mass measuring approximately ___ mm is seen on the ___ wall of the bladder on T2W MRI, with 'light bulb sign' consistent with paraganglioma.
Markedly prominent, intensely enhancing well-defined intramural mass on the bladder wall on arterial phase. Enhancement degree may approach arterial blood pool. Homogeneous enhancement pattern with smooth margins. Persistent enhancement on delayed phase (washout may not be seen).
Report Sentence
A markedly enhancing intramural mass measuring approximately ___ mm is seen on the ___ wall of the bladder on arterial phase; hypervascular paraganglioma should be considered.
The intramural mass shows high signal on DWI but ADC values may be higher than malignant tumors (due to T2 shine-through effect contribution). True ADC values are in the intermediate-to-low range. DWI is not as reliable as T2 and enhancement for differentiating paraganglioma from other bladder tumors — T2 'light bulb sign' and hypervascularity are more specific findings.
Report Sentence
The intramural mass shows high signal on DWI with intermediate ADC value (___ × 10⁻³ mm²/s); T2 shine-through effect may also contribute.
Abnormal uptake in the bladder region on ¹²³I-MIBG or ¹³¹I-MIBG scintigraphy. MIBG (meta-iodobenzylguanidine) is a noradrenaline analogue and is actively taken up by chromaffin cells. MIBG avidity of paraganglioma confirms the diagnosis and screens for multifocal/metastatic disease. Specificity is high (95%+) but sensitivity is variable (75-90%).
Report Sentence
Focal increased uptake in the ___ region of the bladder is seen on MIBG scintigraphy, supporting the diagnosis of paraganglioma.
Well-defined, round, homogeneous hypoechoic intramural mass on the bladder wall on US. Color Doppler demonstrates markedly increased vascularity within the mass — this finding reflects the hypervascular nature of paraganglioma. US can be used for initial detection or screening but MRI is mandatory for characterization.
Report Sentence
A well-defined, hypoechoic intramural mass measuring approximately ___ mm is seen on the ___ wall of the bladder on US, showing markedly increased vascularity on Doppler; paraganglioma should be considered and MRI evaluation is recommended.
The mass shows very prominent, intense, and homogeneous enhancement on contrast-enhanced MRI. Enhancement begins in the arterial phase and persists in the delayed phase. Enhancement degree is much higher than surrounding normal bladder wall. Necrosis or cystic degeneration is rare (in small tumors).
Report Sentence
The bladder intramural mass shows very prominent, intense, and homogeneous enhancement on contrast-enhanced MRI, consistent with hypervascular paraganglioma.
Criteria
Catecholamine-secreting paraganglioma. 50-80% of all bladder paragangliomas. Elevated plasma/urine catecholamine and metanephrine levels.
Distinct Features
Paroxysmal symptoms during micturition, elevated plasma metanephrines, MIBG positive. Preoperative alpha-blockade mandatory (prevention of catecholamine crisis). Imaging findings do not differ from non-functional.
Criteria
Non-catecholamine-secreting paraganglioma. 20-50%. Normal catecholamine levels. Asymptomatic, incidental finding.
Distinct Features
No symptoms but imaging findings (T2 high signal, hypervascularity) are identical. MIBG variable positivity. Preoperative catecholamine workup and alpha-blockade still recommended (risk of occult secretion).
Criteria
Malignant paraganglioma defined by presence of metastasis. 10-15% of all bladder paragangliomas. Histological benign-malignant distinction is difficult.
Distinct Features
Lymphatic or hematogenous metastasis (bone, liver, lung, lymph node). Large size (>5 cm), irregular margins, heterogeneous structure increase suspicion of malignancy. SDHx gene mutation should be screened (hereditary paraganglioma syndrome).
Distinguishing Feature
Urothelial carcinoma shows intermediate T2 signal (markedly different from very high T2 of paraganglioma). Less intense enhancement. Papillary/sessile growth pattern. No catecholamine symptoms during micturition.
Distinguishing Feature
Leiomyoma shows low T2 signal (opposite of paraganglioma's very high signal). Moderate homogeneous enhancement. No DWI restriction. No catecholamine symptoms.
Distinguishing Feature
Cystitis shows diffuse wall thickening without focal intramural mass. T2 signal may increase due to wall edema but focal very high signal (light bulb sign) is not seen. Diffuse enhancement. Inflammatory symptoms predominate.
Distinguishing Feature
Bladder metastasis usually presents in the setting of known primary malignancy, with multiple or diffuse wall involvement. Variable T2 signal (intermediate). Hypervascularity not as prominent as paraganglioma. No catecholamine symptoms. MIBG negative.
Urgency
urgentManagement
surgicalBiopsy
Not NeededFollow-up
specialist-referralDiagnosis of bladder paraganglioma is made by imaging + biochemical tests (plasma metanephrines, 24-hour urine catecholamines) + MIBG scintigraphy. BIOPSY IS CONTRAINDICATED — may trigger catecholamine crisis. Preoperative alpha-blockade (phenoxybenzamine or doxazosin) should be started 2-4 weeks before surgery. Treatment is surgical excision (partial cystectomy or TUR). SDHx gene mutation should be screened (hereditary paraganglioma-pheochromocytoma syndrome). Lifelong follow-up is mandatory — risk of malignant transformation and recurrence. Plasma metanephrines + MIBG/PET are used for follow-up.
Bladder paraganglioma is rare but clinically significant. ~10% are malignant. Hypertensive crisis during micturition guides diagnosis. Alpha-blockade should be initiated before biopsy (catecholamine crisis risk). Treatment is surgical resection (partial cystectomy). May be associated with hereditary syndromes (VHL, SDH mutations, NF1). Long-term follow-up is required (possibility of late recurrence or metastasis).